Clinical Trials for Multiple Myeloma

6 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
Supportive CareVICCBMT12104
02/04/2014
Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD)
TreatmentVICCHEM1377
03/14/2014
A Phase 1 Study of Arry-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
TreatmentVICCHEM1392
03/12/2014
A Phase 1, Open-label, Dose-Escalation Study of the Safety of SNX-5422 Mesylate in Subjects with Refractory Hematological Malignancies
TreatmentVICCHEM1319
08/07/2013
A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
TreatmentVICCHEM12107
03/31/2013
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)
TreatmentVICCMD1188
06/08/2012
An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

You do not have JavaScript enabled. This site works better with JavaScript turned on.